Abstract
Proteolytic stress, resulting from the intracellular accumulation of misfolded or aggregated proteins, which exceed the capacity of the ubiquitin–proteasome system to degrade them, plays a relevant role in neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s chorea. Most of toxic protein aggregates are characterised by the presence of isopeptide bonds (cross-links) catalysed by transglutaminase activity; further, several disease-specific proteins—tau, amyloid-beta, alpha-synuclein, huntingtin—are in vitro and/or in vivo substrates of transglutaminase 2. These findings suggest an important role for transglutaminase 2-mediated cross-linking reactions in neurodegeneration. Therefore, the use of transglutaminase activity inhibitors could ameliorate neuronal cell death. New therapeutic perspectives also arise from the possibility to prevent or reduce protein aggregation by enhancing the activation of heat shock proteins, which have been shown to be potent suppressors of neurodegeneration in cell cultures/animal models. Interestingly, some heat shock proteins have been shown to be in vitro or in vivo cross-linked by transglutaminase 2. These observations seem to suggest that transglutaminase activity could be involved in the stabilization of intracellular protein aggregates by interfering with proteasomal degradation of misfolded proteins. Further studies are needed to validate leading hypotheses and to open new prospects for developing therapeutic tools.
Similar content being viewed by others
Abbreviations
- AD:
-
Alzheimer’s disease
- PD:
-
Parkinson’s disease
- ALS:
-
Amyotrophic lateral sclerosis
- CSF:
-
Cerebrospinal fluid
- ECM:
-
Extracellular matrix
- GGEL:
-
γ-Glutamyl-ε-lysine
- HD:
-
Huntington’s chorea
- HSPs:
-
Heat shock proteins
- NF-kappa B:
-
Nuclear factor-kappa B
- NMDA:
-
N-methyl-d-aspartate
- RA:
-
Retinoic acid
- SCA:
-
Spinocerebellar ataxia
- SBMA:
-
Spinobulbar muscular atrophy
- TG(s):
-
Transglutaminase(s)
- TG2:
-
Tissue transglutaminase
References
Andringa G, Lam KY, Chegary M, Wang X, Chase TN, Bennett MC (2004) Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson’s disease. FASEB J 18:932–934
Bailey CD, Johnson GV (2005) Tissue transglutaminase contributes to disease progression in the R6/2 Huntington’s disease mouse model via aggregate-independent mechanisms. J Neurochem 92:83–92
Battaglia G, Farrace MG, Mastroberardino PG et al (2007) Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders. J Neurochem 100:36–49
Bonelli RM, Aschoff A, Niederwieser G, Heuberger C, Jirikowski G (2002) Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer’s disease. Neurobiol Dis 11:106–110
Boros S, Kamps B, Wunderink L, de Bruijn W, de Jong WW, Boelens WC (2004) Transglutaminase catalyzes differential crosslinking of small heat shock proteins and amyloid-beta. FEBS Lett 576:57–62
Boros S, Ahrman E, Wunderink L, Kamps B, de Jong WW, Boelens WC, Emanuelsson CS (2006) Site-specific transamidation and deamidation of the small heat-shock protein Hsp20 by tissue transglutaminase. Proteins 62:1044–1052
Caccamo D, Currò M, Cusumano G, Crisafulli G, Ientile R (2004) Excitotoxin-induced changes in transglutaminase during differentiation of cerebellar granule cells. Amino Acids 26:197–201
Caccamo D, Campisi A, Currò M, Aguennouz M, Li Volti G, Avola R, Ientile R (2005) Nuclear factor-kappaB activation is associated with glutamate-evoked tissue transglutaminase up-regulation in primary astrocyte cultures. J Neurosci Res 82:858–865
Campisi A, Caccamo D, Raciti G, Cannavò G, Macaione V, Currò M, Macaione S, Vanella A, Ientile R (2003) Glutamate-induced increases in transglutaminase activity in primary cultures of astroglial cells. Brain Res 978:24–30
Campisi A, Caccamo D, Li Volti G, Currò M, Parisi G, Avola R, Vanella A, Ientile R (2004) Glutamate-evoked redox state alterations are involved in tissue transglutaminase upregulation in primary astrocyte cultures. FEBS Lett 578:80–84
Chaudhuri TK, Paul S (2006) Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 273:1331–1349
Chen S, Brown IR (2007) Neuronal expression of constitutive heat shock proteins: implications for neurodegenerative diseases. Cell Stress Chaperones 12:51–58
Currò M, Condello S, Caccamo D, Ferlazzo N, Parisi G, Ientile R (2009) Homocysteine-induced toxicity increases TG2 expression in Neuro2a cells. Amino Acids 36:725–730
Dudek SM, Johnson GV (1994) Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res 651:129–133
Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: nature’s biological glues. Biochem J 368:377–396
Griffin M, Coutts IG, Saint R (2004) International Publication Number WO 2004/1133603, GB patent PCT/GB2004/002569
Ientile R, Caccamo D, Macaione V, Torre V, Macaione S (2002) NMDA-evoked excitotoxicity increases tissue transglutaminase in cerebellar granule cells. Neuroscience 115:723–729
Ientile R, Caccamo D, Marciano MC, Currò M, Mannucci C, Campisi A, Calapai G (2004) Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia. Neurosci Lett 363:173–177
Ientile R, Caccamo D, Griffin M (2007) Tissue transglutaminase and the stress response. Amino Acids 33:385–394
Jeitner TM, Bogdanov MB, Matson WR et al (2001) N(epsilon)-(gamma-l-glutamyl)-l-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington’s disease. J Neurochem 79:1109–1112
Jeitner TM, Matson WR, Folk JE, Blass JP, Cooper AJ (2008) Increased levels of gamma-glutamylamines in Huntington disease CSF. J Neurochem 106:37–44
Jeitner TM, Pinto JT, Krasnikov BF, Horswill M, Cooper AJL (2009) Transglutaminases and neurodegeneration. J Neurochem 109:160–166
Johnson GV, LeShoure R Jr (2004) Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the epsilon-(gamma-glutamyl)lysine bonds formed by transglutaminase activity. J Neurosci Methods 134:151–158
Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 100:2047–2052
Kim SY, Grant P, Lee JH, Pant HC, Steinert PM (1999) Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer’s disease. J Biol Chem 274:30715–30721
Kopito RR, Ron D (2000) Conformational disease. Nat Cell Biol 2:E207–E209
Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY (2004) Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 279:53725–53735
Matthew A, Morimoto RI (1998) Role of the heat-shock response in the life and death of proteins. Ann N Y Acad Sci 851:99–111
Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nature Rev Mol Cell Biol 1:120–129
Mattson MP, Camandola S (2001) NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107:247–254
Miller ML, Johnson GV (1995) Transglutaminase cross-linking of the tau protein. J Neurochem 65:1760–1770
Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6:11–22
Muma NA (2007) Transglutaminase is linked to neurodegenerative diseases. J Neuropathol Exp Neurol 66:258–263
Nemes Z, Devreese B, Steinert PM, VanBeeumen J, Fesus L (2004) Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer’s neurofibrillary tangles. FASEB J 18:1135–1137
Renkawek K, Bosman GJ, de Jong WW (1994) Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia. Acta Neuropathol 87:511–519
Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10(Suppl):S10–S17
Segers-Nolten IM, Wilhelmus MM, Veldhuis G, van Rooijen BD, Drukarch B, Subramaniam V (2008) Tissue transglutaminase modulates alpha-synuclein oligomerization. Protein Sci 17:1395–1402
Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29:15–32
Siegel M, Khosla C (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115:232–245
Singer SM, Zainelli GM, Norlund MA, Lee JM, Muma NA (2002) Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer’s disease. Neurochem Int 40:17–30
Soto C, Estrada LD (2008) Protein misfolding and neurodegeneration. Arch Neurol 65:184–189
Tucholski J, Kuret J, Johnson GV (1999) Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J Neurochem 73:1871–1880
Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR (2005) Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 95:210–220
Vermes I, Steur EN, Jirikowski GF, Haanen C (2004) Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson’s disease indicating apoptosis. Mov Disord 19:1252–1254
Wilhelmus MM, Otte-Holler I, Wesseling P, de Waal RM, Boelens WC, Verbeek MM (2006) Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer’s disease brains. Neuropathol Appl Neurobiol 32:119–130
Zainelli GM, Ross CA, Troncoso JC, Muma NA (2003) Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J Neuropathol Exp Neurol 62:14–24
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Caccamo, D., Currò, M., Condello, S. et al. Critical role of transglutaminase and other stress proteins during neurodegenerative processes. Amino Acids 38, 653–658 (2010). https://doi.org/10.1007/s00726-009-0428-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-009-0428-3